专题：Breast Cancer Treatment Studies

This cluster of papers focuses on molecular research, treatment response, and prognostic markers in breast cancer. It covers topics such as gene expression patterns, molecular subtypes, neoadjuvant therapy, radiotherapy, and the impact of hormone receptors on survival. The papers also discuss the development of clinical practice guidelines for breast cancer management.
最新文献
Abstract GS1-10: Giredestrant vs standard-of-care endocrine therapy as adjuvant treatment for patients with estrogen receptor-positive, HER2-negative early breast cancer: Results from the global Phase III lidERA Breast Cancer trial

article Full Text OpenAlex

Abstract GS2-09: The single-arm confirmatory trial of tamoxifen alone without surgery for low-risk DCIS of the breast with ER-positive HER2-negative (LORETTA trial: JCOG1505)

article Full Text OpenAlex

Oncologic Outcomes of Sentinel Lymph Node Biopsy Versus Targeted Axillary Dissection for Node-Positive Breast Cancer Patients After Neoadjuvant Chemotherapy: A Systematic Review and Meta-Analysis

article Full Text OpenAlex

Evaluating progesterone receptor agonist megestrol plus letrozole for women with early-stage estrogen-receptor-positive breast cancer: the window-of-opportunity, randomized, phase 2b, PIONEER trial

article Full Text OpenAlex

Management of hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer patients: beyond endocrine therapy

article Full Text OpenAlex

Oncological outcomes with and without axillary lymph node dissection in patients with residual micrometastases after neoadjuvant chemotherapy (OPBC-07/microNAC): an international, retrospective cohort study

article Full Text OpenAlex

Effect of adjuvant carboplatin intensified chemotherapy versus standard chemotherapy on survival in women with high risk, early stage, triple negative breast cancer (CITRINE): randomised, open label phase 3 trial

article Full Text OpenAlex

Adjuvant Chemotherapy Use for Hormone Receptor–Positive, ERBB2 -Negative Breast Cancer After RxPONDER Trial

article Full Text OpenAlex

A deep learning framework to stratify Nottingham histologic grade 2 breast tumors based on dynamic contrast-enhanced MRI

article Full Text OpenAlex

20th anniversary of adjuvant trastuzumab: reflections on a breakthrough moment

review Full Text OpenAlex

近5年高被引文献
Breast Cancer Statistics, 2022

article Full Text OpenAlex 2294 FWCI229.5791

Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer

article Full Text OpenAlex 1066 FWCI105.6859

Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer

article Full Text OpenAlex 989 FWCI86.671

Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology

article Full Text OpenAlex 943 FWCI83.2642

Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

article Full Text OpenAlex 708 FWCI171.0419

Triple negative breast cancer: Pitfalls and progress

review Full Text OpenAlex 681 FWCI60.2805

Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer

article Full Text OpenAlex 656 FWCI94.0814

Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial

article Full Text OpenAlex 637 FWCI90.2816

Pathogenesis of Triple-Negative Breast Cancer

review Full Text OpenAlex 609 FWCI54.0151

[Retracted] Global Increase in Breast Cancer Incidence: Risk Factors and Preventive Measures

review Full Text OpenAlex 531 FWCI97.3298